Amphastar Pharmaceuticals (NASDAQ:AMPH) Rating Lowered to Hold at StockNews.com

StockNews.com lowered shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) from a buy rating to a hold rating in a research report released on Friday morning.

Other analysts have also issued reports about the company. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Piper Sandler cut their price target on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a research note on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, Amphastar Pharmaceuticals has an average rating of “Hold” and an average target price of $63.00.

Amphastar Pharmaceuticals Stock Performance

AMPH opened at $50.59 on Friday. The firm has a market cap of $2.46 billion, a P/E ratio of 16.16, a price-to-earnings-growth ratio of 0.96 and a beta of 0.82. Amphastar Pharmaceuticals has a 52-week low of $36.56 and a 52-week high of $65.92. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.63 and a current ratio of 3.52. The business’s fifty day moving average is $48.34 and its 200-day moving average is $43.97.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Wednesday, August 7th. The company reported $0.85 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.10. Amphastar Pharmaceuticals had a return on equity of 29.79% and a net margin of 23.36%. The business had revenue of $182.39 million during the quarter, compared to the consensus estimate of $171.29 million. Sell-side analysts expect that Amphastar Pharmaceuticals will post 3.7 EPS for the current fiscal year.

Insider Transactions at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 17,101 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $43.07, for a total value of $736,540.07. Following the completion of the sale, the director now directly owns 33,971 shares in the company, valued at approximately $1,463,130.97. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 17,101 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $43.07, for a total value of $736,540.07. Following the completion of the sale, the director now directly owns 33,971 shares in the company, valued at approximately $1,463,130.97. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Rong Zhou sold 4,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $48.35, for a total value of $193,400.00. Following the completion of the sale, the executive vice president now owns 118,388 shares of the company’s stock, valued at approximately $5,724,059.80. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 24,101 shares of company stock worth $1,069,350 over the last ninety days. 27.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Silvercrest Asset Management Group LLC increased its holdings in shares of Amphastar Pharmaceuticals by 35.1% during the first quarter. Silvercrest Asset Management Group LLC now owns 112,428 shares of the company’s stock valued at $4,937,000 after acquiring an additional 29,182 shares in the last quarter. Intech Investment Management LLC bought a new stake in shares of Amphastar Pharmaceuticals during the second quarter valued at approximately $426,000. International Assets Investment Management LLC purchased a new position in shares of Amphastar Pharmaceuticals during the third quarter valued at approximately $11,070,000. Nordea Investment Management AB boosted its position in shares of Amphastar Pharmaceuticals by 0.4% during the first quarter. Nordea Investment Management AB now owns 333,014 shares of the company’s stock valued at $14,802,000 after buying an additional 1,209 shares during the last quarter. Finally, Granite Investment Partners LLC boosted its position in shares of Amphastar Pharmaceuticals by 12.7% during the second quarter. Granite Investment Partners LLC now owns 397,514 shares of the company’s stock valued at $15,901,000 after buying an additional 44,744 shares during the last quarter. Institutional investors own 65.09% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.